AAC
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Other Versions of this Article:
AAC.01369-06v1
51/2/752    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zimhony, O.
Right arrow Articles by Jacobs, W. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zimhony, O.
Right arrow Articles by Jacobs, W. R., Jr.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, February 2007, p. 752-754, Vol. 51, No. 2
0066-4804/07/$08.00+0     doi:10.1128/AAC.01369-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Pyrazinoic Acid and Its n-Propyl Ester Inhibit Fatty Acid Synthase Type I in Replicating Tubercle Bacilli{triangledown}

Oren Zimhony,1* Catherine Vilchèze,2 Masayoshi Arai,2 John T. Welch,3 and William R. Jacobs Jr.2

Infectious Diseases Division, Kaplan Medical Center, The Hebrew University and Hadassah Jerusalem, Rehovot, Israel,1 Department of Microbiology and Immunology, Howard Hughes Medical Institute, Albert Einstein College of Medicine, Bronx, New York,2 Department of Chemistry, State University of New York at Albany, Albany, New York3

Received 2 November 2006/ Accepted 4 November 2006

The activity of different analogs of pyrazinamide on Mycobacterium tuberculosis fatty acid synthase type I (FASI) in replicating bacilli was studied. Palmitic acid biosynthesis was diminished by 96% in bacilli treated with n-propyl pyrazinoate, 94% in bacilli treated with 5-chloro-pyrazinamide, and 97% in bacilli treated with pyrazinoic acid, the pharmacologically active agent of pyrazinamide. We conclude that the minimal structure of pyrazine ring with an acyl group is sufficient for FASI inhibition and antimycobacterial activity.

* Corresponding author. Mailing address: Infectious Diseases Division, Kaplan Medical Center, The Hebrew University and Hadassah Jerusalem, P.O. Box 1, Rehovot 76100, Israel. Phone: 972-8-9441993. Fax: 972-8-9441765. E-mail: oren_z{at}clalit.org.il.

{triangledown} Published ahead of print on 13 November 2006.

Antimicrobial Agents and Chemotherapy, February 2007, p. 752-754, Vol. 51, No. 2
0066-4804/07/$08.00+0     doi:10.1128/AAC.01369-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:



Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Clin. Vaccine Immunol. Clin. Microbiol. Rev.
J. Clin. Microbiol. ALL ASM JOURNALS

Copyright © 2007 by the American Society for Microbiology. All rights reserved.